Single nucleotide polymorphisms (SNPs) in FCGR3A can predict the susceptibility of liver transplant (LT) recipients to bloodstream infections (BSI) and clinical outcomes following living-donor LT (LDLT). Here, we retrospectively analyzed the relationship of adoptive immunotherapy with activated natural killer (NK) cells from perfusate effluents of liver allografts against BSI following LDLT. Higher BSI incidence and lower survival were observed in LT recipients with FcγRIIIa (158F/F or F/V) (n = 81) who did not receive adoptive immunotherapy (n = 55) than in those who did (n = 26) (BSI frequency, 36.4% vs. 11.5%; p = .033; log-rank p = .047). After matching patient background using propensity score, similar results were obtained (BSI ratio, 41.7% vs. 12.5%; p = .049; log-rank p = .039). The predominant BSI pathogens in patients who did and did not receive adoptive immunotherapy were gram-negative rods (n = 3, 100%) and gram-positive cocci (GPC) (n = 15, 65.2%), respectively. The proportion of NK cells administered to patients with BSI was significantly lower than that administered to patients without BSI (Number: 80.3 (29.9-239.2) × 106 cells vs. 37.1 (35.6-50.4) × 106 ; p = .033, percentage; 14.1 (13.3-17.8)% vs. 34.6 (16.5-47)%, p = .0078). Therefore, adoptive immunotherapy with NK cells was associated with the reduced post-transplant BSI related to GPCs due to FcγRIIIa SNP in LT recipients.
Lung cancer with a five-year survival rate of less than 20% is currently one of the most common malignancies worldwide. Cell-based immunotherapy showed promising results over the past two decades, but some patients still experience disease progression. Numerous studies identified the critical role of the tumor microenvironment in tumor progression, immune evasion, and treatment response. The dynamic interplay between the tumor and its surrounding microenvironment significantly influences both tumor behavior and the immune response. One of the critical components of this interplay is how essential nutrients and structural support are involved in tumor growth per se and cancer pathophysiology in general. A comprehensive understanding of the underlying mechanisms and molecular players critical to the tumor microenvironment is crucial to optimize immunotherapy strategies. This review examines key therapeutic targets in lung cancer, uncovering the complex interactions within the tumor microenvironment to enhance the efficacy of immunotherapy.